BEAM

Beam Therapeutics Inc (BEAM) | Rumor.io

Beam Therapeutics

BEAM

Attention (50-day avg)0%

Attention rank (50-day avg)#797

Bullish sentiment (50-day avg)72%

Price to earnings ratio-29.9

Market capitalization2.5B

Earnings per share-0.69

Dividend yield (TTM)—

Revenue (annual)139.7M

Net income (annual)-80M

Social

What share of all stock conversation is about BEAM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% +0	0% -0.01

Sep 8

Beam Therapeutics Inc. (BEAM) presented promising 18 months of follow-up data from its Phase 1/2 clinical trial in Alpha-1 Antitrypsin Deficiency (AATD), demonstrating long-term durability of in vivo correction of AATD's disease-causing mutation.
The company's latest clinical data update was met with a sell-off, but prices have since recovered, and the update did not raise any long-term safety issues, with dosing in the pivotal portion of the study underway.
The short interest in BEAM has increased, with 24.37M shares sold short, representing 36.71% of the float, and 23.69% of shares outstanding, with 16.08 days to cover.

Generated by AI

Sentiment

Of the messages about BEAM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	60% new	53.38% -46.62	85.82% -0.22
Bearish	0%	40% -60	46.62% +46.62	14.18% +0.22

Bullish· Jan 12

Beam Therapeutics Inc. ($BEAM) has a strong path for accelerated approval in AATD, a disease with a major unmet need, which is a significant lift for the genome editing space.
The company's deal with the FDA for its gene-editing drug, BEAM-302, has been well-received by investors, pushing the stock to a 10-month high.
Beam Therapeutics has a strong momentum setup, with buyers defending levels and pushing higher, and has the potential for continued upside as it continues to build momentum.

Bearish· Oct 20

Beam Therapeutics Inc. may be forced to raise additional capital to achieve SCD approval, which could negatively impact investor sentiment.
The company's restructuring plans have led to a downgrade from Leerink, potentially affecting the stock's performance.
Beam Therapeutics has experienced significant declines in value, with a 86.52% drop from June 2021, and has laid off staff while reportedly filling the pockets of its CEO and board.

Generated by AI

Topics

Of the messages about BEAM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	52.48%	52.48%	76.5%	77.39%
Technical Analysis	0%	0%	0.79%	10.15%
Analysts	0%	0%	0%	2.1%
Controversies	47.52%	47.52%	22.71%	7.31%
Earnings	0%	0%	0%	0.24%
Macro	0%	0%	0%	2.81%

Feb 24

Beam Therapeutics Inc. ($BEAM) has announced a $500M strategic financing facility with Sixth Street, providing non-dilutive capital to fund the potential launch of risto-cel in sickle cell disease (SCD) and pivotal path for BEAM-302.
The company has secured a cash runway into mid-2029, extending its cash balance to $1.25B, and reported a surprising Q4 profit and a new program targeting PKU with IND planned 2026.
Beam Therapeutics' $500M facility is a high-interest bet, but it also allows the company to fund its risto-cel launch in SCD and pivotal path for BEAM-302, and has been seen as a sign of strength in the biotech industry.

Generated by AI

Community

Of the messages about BEAM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	89.05%	52.61%	63.69%
Newcomers	0%	10.95%	47.39%	36.31%

Regulars· Feb 24

Beam Therapeutics has announced a $500M strategic financing deal with Sixth Street for non-dilutive capital to fund its risto-cel launch in sickle cell disease.
The company's PKU program (BEAM-304) may involve licensing prime editing from PRIME for non-transition mutations, allowing PRIME to advance in AATD.
Beam's in vivo gene editing programs, including PKU and GSD1a, are progressing, with INDs filed for several programs, but LNP safety remains a concern.

Newcomers· Mar 26

Newcomers are discussing Beam Therapeutics' Phase 1/2 trial data for BEAM-302, a treatment for Alpha-1 AATD.
The trial's focus is on evaluating the safety and efficacy of BEAM-302 in patients with Alpha-1 AATD.
The ongoing trial is expected to provide valuable insights into the treatment's potential in addressing this rare genetic disorder.

Generated by AI

News

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)

Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028–2029, cash runway/dilution risks, valuation vs peers—read now.

1d agoSeeking Alpha

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock

1d agoBarchart.com

Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business is generating in sales today? Over the past 5 years the stock has fallen 72.1%, which puts the focus squarely on whether the revenue it produces can still justify even the current market value. Recent coverage of the in vivo gene editing market highlights Beam Therapeutics as a key participant...

6d agoYahoo Finance

Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View

18d agoSeeking Alpha

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]

19d agoYahoo Finance UK

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow (NASDAQ:BEAM) 2026-09-10

19d agoSeeking Alpha

Also Discussed

Investors talking about BEAM also mention

#	Name	Attention
1	Intellia Therapeutics, Inc.NTLA	0%+0
2	Prime Medicine, Inc.PRME	0%-0.01
3	CRISPR Therapeutics AGCRSP	0%0
4	Editas Medicine, Inc.EDIT	0%+0
5	Caribou Biosciences, Inc.CRBU	0%0
6	VERV - Verve Therapeutics, Inc.	——
7	Twist Bioscience CorporationTWST	0%-0.02
8	Fate Therapeutics Inc.FATE	0%new
9	Century Therapeutics IncIPSC	0%0
10	Precision BioSciences, Inc.DTIL	0%new

Beam Therapeutics Inc

Healthcare
Biotechnology

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company works on therapies designed to make targeted, single-letter changes in DNA without creating double-strand breaks, supporting programs aimed at serious genetic and hematologic diseases. Its current pipeline includes research and clinical candidates across areas such as blood disorders, liver diseases, and other rare conditions. Beam Therapeutics also maintains integrated capabilities in gene editing, delivery, and internal manufacturing to support the development of its therapeutic candidates. Based in Cambridge, Massachusetts, Beam Therapeutics plays a role in the advanced genomics and gene-editing market, where precision medicine approaches are being applied to address diseases with limited treatment options.

Website

Location

238 Main Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about BEAM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% +0	0% -0.01

Sep 8

Beam Therapeutics Inc. (BEAM) presented promising 18 months of follow-up data from its Phase 1/2 clinical trial in Alpha-1 Antitrypsin Deficiency (AATD), demonstrating long-term durability of in vivo correction of AATD's disease-causing mutation.
The company's latest clinical data update was met with a sell-off, but prices have since recovered, and the update did not raise any long-term safety issues, with dosing in the pivotal portion of the study underway.
The short interest in BEAM has increased, with 24.37M shares sold short, representing 36.71% of the float, and 23.69% of shares outstanding, with 16.08 days to cover.

Generated by AI

Sentiment

Of the messages about BEAM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	60% new	53.38% -46.62	85.82% -0.22
Bearish	0%	40% -60	46.62% +46.62	14.18% +0.22

Bullish· Jan 12

Beam Therapeutics Inc. ($BEAM) has a strong path for accelerated approval in AATD, a disease with a major unmet need, which is a significant lift for the genome editing space.
The company's deal with the FDA for its gene-editing drug, BEAM-302, has been well-received by investors, pushing the stock to a 10-month high.
Beam Therapeutics has a strong momentum setup, with buyers defending levels and pushing higher, and has the potential for continued upside as it continues to build momentum.

Bearish· Oct 20

Beam Therapeutics Inc. may be forced to raise additional capital to achieve SCD approval, which could negatively impact investor sentiment.
The company's restructuring plans have led to a downgrade from Leerink, potentially affecting the stock's performance.
Beam Therapeutics has experienced significant declines in value, with a 86.52% drop from June 2021, and has laid off staff while reportedly filling the pockets of its CEO and board.

Generated by AI

Topics

Of the messages about BEAM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	52.48%	52.48%	76.5%	77.39%
Technical Analysis	0%	0%	0.79%	10.15%
Analysts	0%	0%	0%	2.1%
Controversies	47.52%	47.52%	22.71%	7.31%
Earnings	0%	0%	0%	0.24%
Macro	0%	0%	0%	2.81%

Feb 24

Beam Therapeutics Inc. ($BEAM) has announced a $500M strategic financing facility with Sixth Street, providing non-dilutive capital to fund the potential launch of risto-cel in sickle cell disease (SCD) and pivotal path for BEAM-302.
The company has secured a cash runway into mid-2029, extending its cash balance to $1.25B, and reported a surprising Q4 profit and a new program targeting PKU with IND planned 2026.
Beam Therapeutics' $500M facility is a high-interest bet, but it also allows the company to fund its risto-cel launch in SCD and pivotal path for BEAM-302, and has been seen as a sign of strength in the biotech industry.

Generated by AI

Community

Of the messages about BEAM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	89.05%	52.61%	63.69%
Newcomers	0%	10.95%	47.39%	36.31%

Regulars· Feb 24

Beam Therapeutics has announced a $500M strategic financing deal with Sixth Street for non-dilutive capital to fund its risto-cel launch in sickle cell disease.
The company's PKU program (BEAM-304) may involve licensing prime editing from PRIME for non-transition mutations, allowing PRIME to advance in AATD.
Beam's in vivo gene editing programs, including PKU and GSD1a, are progressing, with INDs filed for several programs, but LNP safety remains a concern.

Newcomers· Mar 26

Newcomers are discussing Beam Therapeutics' Phase 1/2 trial data for BEAM-302, a treatment for Alpha-1 AATD.
The trial's focus is on evaluating the safety and efficacy of BEAM-302 in patients with Alpha-1 AATD.
The ongoing trial is expected to provide valuable insights into the treatment's potential in addressing this rare genetic disorder.

Generated by AI

Beam Therapeutics

Social

Sep 8

Bullish· Jan 12

Bearish· Oct 20

Feb 24

Regulars· Feb 24

Newcomers· Mar 26

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock

Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow (NASDAQ:BEAM) 2026-09-10

Also Discussed

Beam Therapeutics Inc

Company Information

Location

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock

Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows

Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View

Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency - Slideshow (NASDAQ:BEAM) 2026-09-10

Also Discussed

Social

Sep 8

Bullish· Jan 12

Bearish· Oct 20

Feb 24

Regulars· Feb 24

Newcomers· Mar 26